Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.
OPN-6602 Granted Orphan Drug Designation in R/R Multiple Myeloma
Data from a multiple myeloma mouse xenograft model demonstrated promising tumor regression activity from OPN-6602 monotherapy and in combination with standard of care agents.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Cilta-Cel Achieves High MRD Negativity Rates in Lenalidomide-Refractory Multiple Myeloma
Updated CARTITUDE-4 trial data show cilta-cel induces deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma
Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.
Clinical Trials Underestimate HRQOL Burden on R/R Myeloma Population
A retrospective systemic literature review showed that increased lines of therapy led to decreased HRQOL in patients with relapsed/refractory myeloma.